Using this new approach, the authors demonstrated robust degradation of ERα, the chronic myeloid leukemia (CML)-causative BCR–Abl fusion protein, BRD4 and PDE4 proteins in cells [102]. The gene discussed is BRD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.